Incannex Healthcare Limited (IHL.ASX) is a clinical stage pharmaceutical development company developing unique medicinal cannabis pharmaceutical products and psychedelic medicine therapies for the treatment of Generalised Anxiety Disorder (GAD), Obstructive Sleep Apnoea (OSA), Traumatic Brain Injury (TBI)/Concussion, rheumatoid arthritis, inflammatory bowel disease and inflammatory lung conditions (ARDS, COPD, Asthma, Bronchitis).
FDA registration and marketing approval, subject to ongoing clinical success, is being pursued for each product and therapy under development.
Each indication represents major global markets and currently have either no, or limited, existing registered pharmacotherapy (drug) treatments available to the public, raising the possibility of patients receiving Government subsidies for products that demonstrate suitable safety and efficacy profiles in clinical trials.
Incannex has a strong patent filing strategy as it develops its products and therapies in conjunction with its medical and scientific advisory board and its collaborative partners, including Monash University and The Alfred Hospital.
Troy Valentine, Chairman
Troy Valentine is a finance professional with managerial and Board experience spanning over 25 years. Originally from Perth, Troy began his career with Hartley Poynton in 1994, before moving to Patersons Securities in 2000 where he was appointed associate director of private clients. Mr Valentine has significant corporate advisory and capital raising experience, specifically with small to mid-cap size companies, and is currently co-founder and director of the boutique corporate advisory group Alignment Capital, based in Melbourne.
Joel Latham, CEO and Managing Director
Joel Latham is the CEO and Managing Director of Impression Healthcare and is responsible for the Company’s commercial operations. Mr Latham is widely experienced in management and operational matters, having over 13 years’ experience in management in multiple major blue-chip organisations.
Prior to his appointment to CEO and Managing Director, Joel was the General Manager of Impression Healthcare for three years. During this time, he was instrumental negotiation and procurement of many contracts and collaborations, including with Cannvalate, AFL and NRL.
Dr Sud Agarwal, Chief Medical Officer and Director
Dr Agarwal is the Chief Medical Officer of Impression Healthcare, responsible for strategic decision-making and oversight over the Company’s cannabinoid clinical program and pipeline of proprietary products.
Dr Agarwal is a qualified anaesthetist and is considered one of the most influential people in the medicinal cannabis sector, as evidenced by being a recent keynote speaker at the World Cannabis Congress (held in Canada).
He is also the current CEO of Cannvalate Pty Ltd, which is Australia’s largest distributor of medicinal cannabis products. Before Impression Healthcare, Sud was the Medical Director of ASX-listed, Cann Group Limited.
Peter Widdows, Director
Peter Widdows is a Chartered Accountant with deep experience in all functions of business.Peter has over 17 years of experience in senior global executive positions at H.J. Heinz Corporation. He was the CEO and Managing Director of H.J. Heinz Company Australia between February 2003 and October 2008. During his tenure, Heinz Australia sales trebled, and the net profit grew by over 5 time. Following his role in Australia, he moved into a regional CEO role covering Australasia and a large part of Asia, with responsibility for 18,500 employees and revenues of US$1.8B.
Glenn Fowles, Company Secretary
Glenn Fowles has 30 years’ experience in accounting, compliance and funds management and has been a Company Director and Company Secretary for multiple ASX listed companies in recent years.
Most notably, Mr Fowles spent 17 years at Contango Asset Management Ltd in which he had numerous roles including executive director, COO and Company Secretary. Prior to that, Glenn was the Chief Operating Officer and Executive Director of HSBC Asset Management.